Resumen de SEOM-TTCC clinical guideline in nasopharynx cancer (2021)

Antonio Rueda Domínguez, Beatriz Cirauqui Cirauqui, Almudena García Castaño, Ruth Álvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fernández, Leticia Iglesias Rey, J. Rubió Casadevall, Virginia Arrazubi Arrula, Ricard Mesía Nin

• Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.